ClinicalTrials.gg
RecruitingNCT06227156Updated May 23, 2024

Disitamab Vedotin in the Treatment With HER2- Expression, Subjects With Locally Advanced or Metastatic Castration-resistant Prostate Cancer

A Phase 2 interventional study of Disitamab Vedotin Injection in Castration-resistant Prostate Cancer, sponsored by RemeGen Co., Ltd.. Recruiting at 3 sites in China. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-23.

Sponsored by RemeGen Co., Ltd. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as recruiting.
  • Started Apr 2024; still recruiting 2 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 541 studies in Prostatic Neoplasms with a site in China — 281 open to participants now, 342 under way, 51 of them phase 3. Prostatic Neoplasms · China.

Planned enrollment
314th of 435
40 · median 100
Started
2024
with 87 others
Phase 2
84 of 541
51 open now
Primary completion
2025-12
later than 80 of 341 live
Registered
274th of 541
by date

Among the 541 studies in Prostatic Neoplasms with a site in China, this one is the 314th largest by planned enrollment of the 435 interventional ones that give a count, is one of 88 that started in 2024, is one of 84 in phase 2, reaches primary completion later than 80 of the 341 other live ones, and was the 274th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

281 of the 541 studies in Prostatic Neoplasms with a site in China are open now. Recruiting first, the newest first:

276 more — sign in →

All 281 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 541 studies in Prostatic Neoplasms with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the effectiveness of Disitamab Vedotin in the treatment of subjects with locally advanced or metastatic castration-resistant prostate cancer.

Read the detailed description

This is a Multicenter Open Phase II to Evaluate the Safety, Efficacy and Pharmacokinetic Characteristics of Disitamab Vedotin in the Treatment With HER2- Expression, Subjects with locally advanced or metastatic castration-resistant prostate cancer.

The study plans to enroll 40 subjects with locally advanced or metastatic CRPC with HER2 expression (IHC 1+ and above) who have been treated with androgen deprivation therapy and novel hormone therapy. Eligible subjects were enrolled and received RC48 intravenous infusion at a dose of 2.0 mg/kg every 2 weeks. Subjects received medication until disease progression, intolerable toxicity, active withdrawal, death, or study termination by the sponsor.

03

Conditions studied

  • Castration-resistant Prostate Cancer

Browse trials for

Keywords

  • Metastatic Castration-resistant prostate cancer.
  • HER2- expression
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years
  2. Pathology confirmed prostate adenocarcinoma
  3. Locally advanced or prostate cancer
  4. PCWG3 criteria-compliant prostate cancer progression occurs during androgen deprivation therapy (or bilateral scrotal excision). Progression will be determined based on at least 1 of the following criteria: PSA progression: defined as 2 consecutive increases in PSA, separated by at least 1 week, relative to the previous reference value. If a confirmed PSA increase is the only indicator of progression, then 1 ng/mL is the minimum starting value; Soft tissue progression: defined as an increase of ≥20% in the sum of the diameters of all target lesions (short-axis for lymph node lesions and long-axis for non-lymph node lesions) relative to the sum of the smallest diameters at the start of treatment or the presence of one or more new lesions; Bone lesion progression: defined as the detection of at least two additional new lesions on bone scan.
  5. Serum testosterone level ≤ 50 ng/dL (or ≤ 1.73 nmol/L), prior to the first study drug administration;
  6. Continuous androgen deprivation therapy (ADT) with LHRH agonists or LHRH antagonists or previous bilateral orchiectomy (surgical debridement) during the study period;
  7. Confirmed expression (IHC 1+, 2+, 3+), HER2 gene amplification, or HER2 gene mutation;
  8. Subjects were able to provide paraffin blocks or at least 5 paraffin embedded sections (white pieces) for HER2 detection, and the presence of HER2 expression was confirmed by central laboratory tests (immunohistochemistry 1+, 2+, 3+);
  9. Previous medical androgen deprivation therapy (or bilateral scrotal excision) and new hormone therapy (e.g. abiraterone, enzalutamide) and have developed disease progression
  10. The following criteria should be met within 7 days prior to the first study dose:

    1. ≥ 9 g/dL;
    2. (ANC) ≥ 1.5 × 109/L;
    3. count ≥ 100 × 109/L;
    4. serum total ≤ 1.5 times the (ULN);
    5. without liver metastasis, and aspartate aminotransferase ≤ 2.5 × ULN; with liver metastasis, alanine aminotransferase and aspartate aminotransferase ≤ 5 × ULN;;
    6. albumin (ALB) ≥ 25 g/L;
    7. blood creatinine ≤ 1.5 × ULN, or calculated according to the formula, creatinine clearance (CrCl) ≥ 50 mL/min;
    8. (LVEF) ≥ 50%;
  11. Physical Status Score of 0-1
  12. Expected survival ≥ 6 months
  13. Subjects whose spouses are of childbearing age must agree to use during the study and for 6 months after the last dose; sperm donation is not permitted during the study and for 6 months after the last dose
  14. Ability to understand and sign an form.

Exclusion criteria

Exclusion Criteria:

  1. Systematic chemotherapy, novel hormone therapy, targeted therapy, immunotherapy, or other antitumor therapy (including 5-alpha reductase inhibitors, oestrogens, and medroxyprogesterone, etc.)was administered prior to the initial study drug, and treatment ended within 5 half-lives (or 2 weeks, whichever is shorter) of the initial study drug. Except maintenance castration therapy (LHRH agonists or LHRH antagonists) or bone therapy(e.g., denosumab, zoledronic acid); In the first study, Chinese medicines with anti-tumor indications were used 2 weeks before administration.
  2. Known active central nervous system (CNS) metastases and/or carcinomatous meningitis (subjects who have been treated for may be enrolled in this study provided they have stable disease [no evidence of progression as determined by imaging for at least 4 weeks prior to study dosing and and all neurological symptoms have fully recovered], there is no evidence of new or enlarging brain metastases, and discontinuation of therapy at least 7 days prior to the first dose of the trial treatment. (This exception does not include carcinomatous meningitis, which should be excluded regardless of whether it is clinically stable or not).
  3. Has received anti- therapy ;
  4. Major surgery, systemic radiotherapy or biologic therapy within 4 weeks prior to first study drug administration, or minor surgery or local radiotherapy within 1 week prior to enrollment;
  5. Toxicity due to prior antineoplastic therapy that has not recovered to (CTCAE Version 5.0) Grade 1 or below, with the exception of alopecia and abnormalities in laboratory tests or toxicity associated with LHRH agonists or LHRH antagonists that are not considered by the investigator to pose a safety risk;
  6. Known allergic reactions to components of the study treatment or its analogues
  7. Diagnosis of other that are expected to affect or may interfere with disease assessment. Except for cured non-melanoma skin cancer and superficial bladder cancer
  8. Severe and/or persistent infection within 14 days prior to starting the study drug
  9. Serum virological tests: positive test result with a positive HBV DNA copy number; positive HCVAb test result; positive HIVAb test result;
  10. Known serious cardiovascular disease, including any of the following: myocardial infarction, thrombotic event, or unstable angina pectoris in the past 3 months; chronic heart failure, (NYHA) class II or higher; presence of unstable arrhythmia; uncontrolled hypertension;
  11. Combined grade 2 and higher (CTCAE version 5.0) peripheral neuropathy
  12. Presence of other systemic diseases that, in the judgement of the investigator, are not under stable control, including diabetes mellitus, liver cirrhosis, pneumonitis, and obstructive pulmonary disease;
  13. In the judgement of the investigator, there were other circumstances that made participation in the study unsuitable.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Disitamab Vedotin

    Disitamab Vedotin Q2W arm

    Drug: Disitamab Vedotin Injection

Interventions

06

What researchers measure

Primary outcomes

  1. Radiographic progression free survival,rPFS

    Define imaging disease progression according to RECIST v1.1 (for all lesions except bone lesions) or PCWG3 (for bone lesions) as the time from the first dose of the drug to the time when the imaging shows disease progression or death.

    Time frame: Up to approximately 2 years

Secondary outcomes

  1. Objective remission rate (ORR)

    ORR assessed according to the evaluation criteria for the efficacy of solid tumors (RECIST 1.1)

    Time frame: Up to approximately 2 years

  2. Disease Control Rate (DCR)

    Percentage of patients with complete response, partial response, or stable disease for a certain period of time according to RECIST v1.1.

    Time frame: Until progression, assessed up to approximately 2 years

  3. Time to PSA progression(TTPP)

    Defined as time from date of first dose to first PSA progression

    Time frame: Until progression, assessed up to approximately 2 years

  4. Duration of response (DoR)

    Defined as the time from the date of first documented response (CR/PR) until the first progression or death in the absence of disease progression by Investigators assessment according to RECIST 1.1

    Time frame: Until progression, assessed up to approximately 2 years

  5. PSA response rate

    Percent of subjects with different degree of decrease in PSA compared to baseline

    Time frame: Until progression, assessed up to approximately 2 years

  6. Time to first symptomatic bone-related event (SSE)

    Defined as the time from the first dose to the first occurrence of SSE.

    Time frame: Until progression, assessed up to approximately 2 years

  7. Overall Survival (OS)

    OS was defined as the time from the date of randomization to the date of death from any cause.

    Time frame: Up to approximately 2 years

  8. Cmax of RC48

    Peak Plasma Concentration of RC48

    Time frame: Up to approximately 2 years

  9. AUC of RC48

    Area under the plasma concentration versus time curve of RC48

    Time frame: Up to approximately 2 years

  10. AUC of MMAE

    Area under the plasma concentration versus time curve of MMAE

    Time frame: Up to approximately 2 years

  11. Immunogenicity of RC48

    Anti-drug antibody (ADA) of RC48 positive samples, etc.

    Time frame: up to approximately 2 years

  12. Percentage of Participants With Adverse Events (AEs)

    Number of participants with adverse effects of treatment. Frequency and severity of adverse effects of treatment as assessed by NCI CTCAE v5.0

    Time frame: Up to approximately 2 years

  13. Incidence of laboratory tests abnormalities

    To be summarized using descriptive statistics

    Time frame: Up to follow-up period, approximately 2 years

  14. Incidence of ECG abnormalities

    To be summarized using descriptive statistics

    Time frame: Up to follow-up period, approximately 2 years

07

Study locations

1 of 3 sites recruiting
  • Peking University First Hospital
    Beijing, Beijing 100034, China
    Not yet recruiting
    • Zhisong He, M.D · Contact
    • Zhisong He, M.D · Principal investigator
  • The Third Medical Center of PLA General Hospital
    Beijing, Beijing 1000853, China
    Not yet recruiting
    • Xu Zhang, M.D · Contact
    • Xu Zhang · Principal investigator
  • Beijing Cancer Hospital
    Beijing, Beijing 100142, China
    Recruiting
    • Jun Guo, Ph.D · Contact
    • Jun Guo, Ph.D · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2024 (actual). Primary completion is estimated for Dec 2025, 20 months after the start.

Of 114 industry-sponsored phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 45. This study's planned 20 months is below that.

Counting every sponsor, half of 724 studies reached it within 53 months; a quarter within 34 and three quarters within 81.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 17, 2024
First posted
Jan 26, 2024
StartActual
Apr 8, 2024
Primary completionEst.
Dec 2025
CompletionEst.
Jun 2026
Last update
May 23, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06227156
Lead sponsor
RemeGen Co., Ltd.
Responsible party
Sponsor
First posted
Jan 26, 2024
Start date
Apr 8, 2024
Primary completion
Dec 2025 (estimated)
Completion
Jun 2026 (estimated)
Last update
May 23, 2024

Study contacts

Jianmin Fang, Ph.D
Contact
Jianminfang@hotmail.com
+8610-58075763
Jianmin Fang, Ph.D
study director · RemeGen Co., Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Disitamab vedotin

Start the discussion